Suzano SA ADR's income statement, balance sheet and cash flow statement as filed with the SEC (10-K and 10-Q), with the latest fiscal years and quarters. In its latest fiscal year (Dec 31, 2025 · FY), Suzano SA ADR reported revenue of $50.1B (+5.7% year on year).
| Line item | Dec 31, 2025 · FY | Dec 31, 2024 · FY | Dec 31, 2023 · FY | Dec 31, 2022 · FY |
|---|---|---|---|---|
| NET SALES | $50.1B | $47.4B | $39.8B | $49.8B |
| Cost of sales | ($33.9B) | ($27.4B) | ($25.1B) | ($24.8B) |
| GROSS PROFIT | $16.2B | $20.0B | $14.7B | $25.0B |
| Selling expense | ($3.3B) | ($2.9B) | ($2.6B) | ($2.5B) |
| General and administrative expense | ($2.8B) | ($2.6B) | ($1.9B) | ($1.7B) |
| Loss from associates and joint ventures | ($409.2M) | ($13.8M) | ($19.4M) | $284.4M |
| Other operating income, net | $934.9M | $1.3B | $2.1B | $1.1B |
| Profit (loss) from operating activities | $10.6B | $15.7B | $12.2B | $22.2B |
| Finance costs | ($6.9B) | ($5.5B) | ($4.7B) | ($4.6B) |
| Finance income | $1.8B | $1.7B | $1.8B | $967.0M |
| Derivative gains, net | $7.3B | ($9.1B) | $5.5B | $6.8B |
| Foreign exchange gain (loss) | $7.6B | ($15.9B) | $3.1B | $3.3B |
| Profit (loss) before tax | $20.4B | ($13.1B) | $18.0B | $28.7B |
| Current Tax Expense (Income) And Current Social Contribution Tax Expense (Income) | ($518.4M) | ($1.4B) | ($395.4M) | ($510.9M) |
| Adjustments for deferred tax expense | ($6.5B) | $7.4B | ($3.5B) | ($4.7B) |
| Profit (loss) | $13.4B | ($7.0B) | $14.1B | $23.4B |
| Resulted of the year attributable to controlling shareholders' | $13.4B | ($7.1B) | $14.1B | $23.4B |
| Non-controlling interest | $29.5M | $29.5M | $21.5M | $13.3M |
| Basic earnings (loss) per share | $10.84 | -$5.59 | $10.86 | $17.58 |
| Diluted earnings (loss) per share | $10.82 | -$5.59 | $10.85 | $17.57 |
| Line item | Jun 30, 2026 · YTD | Mar 31, 2026 · Q4 | Sep 30, 2025 · YTD | Jun 30, 2025 · YTD |
|---|---|---|---|---|
| Net sales | $22.6B | $11.0B | $37.0B | $24.8B |
| Cost of sales | ($16.6B) | ($7.8B) | ($24.8B) | ($16.3B) |
| Gross profit | $6.0B | $3.2B | $12.2B | $8.5B |
| Selling expense | ($1.6B) | ($752.0M) | ($2.4B) | ($1.6B) |
| General and administrative expense | ($1.2B) | ($682.8M) | ($2.0B) | ($1.3B) |
| Loss from associates and joint ventures | ($25.6M) | ($20.4M) | ($268.4M) | ($189.1M) |
| Other operating income, net | $1.4B | $69.5M | ($409.8M) | ($274.1M) |
| Profit (loss) from operating activities | $4.6B | $1.8B | $7.1B | $5.1B |
| Finance costs | ($3.5B) | ($1.8B) | ($5.1B) | ($3.2B) |
| Finance income | $1.0B | $486.0M | $1.3B | $822.1M |
| Derivative gains, net | $4.0B | $3.0B | $7.4B | $6.4B |
| Foreign exchange gain (loss) | $3.1B | $2.9B | $9.5B | $8.2B |
| Profit (loss) before tax | $9.2B | $6.4B | $20.3B | $17.3B |
| Current Tax Expense (Income) And Current Social Contribution Tax Expense (Income) | ($25.9M) | $87.5M | ($472.4M) | ($310.5M) |
| Adjustments for deferred tax expense | ($3.0B) | ($2.2B) | ($6.5B) | ($5.6B) |
| Net income for the period | $6.1B | $4.3B | $13.3B | $11.4B |
| Resulted of the year attributable to controlling shareholders' | $6.1B | $4.3B | $13.3B | $11.3B |
| Non-controlling interest | $13.5M | $6.6M | $22.5M | $14.7M |
| Basic earnings (loss) per share | $4.94 | $3.48 | $10.75 | $9.17 |
| Diluted earnings (loss) per share | $4.93 | $3.48 | $10.72 | $9.15 |
| Line item | Dec 31, 2025 · FY | Dec 31, 2024 · FY | Dec 31, 2023 · FY | Dec 31, 2022 · FY |
|---|---|---|---|---|
| Cash and cash equivalents | $15.2B | $9.0B | $8.3B | $9.5B |
| Marketable securities | $9.9B | $13.0B | $12.8B | $7.5B |
| Trade accounts receivable | $6.6B | $9.1B | $6.8B | $9.6B |
| Inventories | $8.2B | $8.0B | $5.9B | $5.7B |
| Recoverable taxes | $887.1M | $1.1B | $888.5M | $549.6M |
| Current Tax Assets Income Tax Related | $659.2M | — | — | — |
| Derivative financial instruments | $1.6B | $1.0B | $2.7B | $3.0B |
| Advances to suppliers | $76.8M | $92.1M | $113.7M | $108.1M |
| Other assets | $858.0M | $889.2M | $925.1M | $1.0B |
| Total current assets | $43.9B | $42.2B | $38.6B | $37.1B |
| Marketable securities | $319.7M | $392.0M | $443.4M | $419.1M |
| Recoverable taxes | $945.7M | $1.2B | $1.4B | $1.4B |
| Derivative financial instruments | $8.0B | $2.9B | $1.8B | $1.8B |
| Advances to suppliers | $2.8B | $2.5B | $2.2B | $1.6B |
| Judicial deposits | $418.3M | $488.0M | $361.7M | $362.6M |
| Other assets | $187.1M | $156.9M | $182.5M | $280.0M |
| Biological assets | $26.1B | $22.3B | $18.3B | $14.6B |
| Investments accounted for using equity method | $1.2B | $1.8B | $608.0M | $612.5M |
| Property, plant and equipment | $64.3B | $65.0B | $59.3B | $50.7B |
| Right of use | $5.3B | $5.2B | $5.2B | $5.1B |
| Intangible | $13.0B | $13.9B | $14.7B | $15.2B |
| Total non-current assets | $124.1B | $123.8B | $105.0B | $96.1B |
| TOTAL ASSETS | $167.9B | $165.9B | $143.6B | $133.2B |
| Trade accounts payable | $5.1B | $6.0B | $5.6B | $6.2B |
| Loans, financing and debentures | $3.0B | $10.5B | $4.8B | $3.3B |
| Lease liabilities | $857.8M | $872.2M | $753.4M | $672.2M |
| Derivative financial instruments | $1.2B | $2.8B | $578.8M | $667.7M |
| Taxes payable | $240.0M | $363.7M | $443.5M | $449.1M |
| Income taxes payable | $218.2M | — | — | — |
| Payroll and charges | $1.1B | $1.2B | $766.9M | $674.5M |
| Liabilities for assets acquisitions and subsidiaries | $17.7M | $21.2M | $93.4M | $1.9B |
| Dividends payable, non-cash assets distributions | $1.4B | $2.2B | $1.3B | $5.1M |
| Advances from customers | $132.4M | $145.2M | $172.4M | $131.4M |
| Other liabilities | $429.5M | $346.8M | $339.7M | $494.2M |
| Total current liabilities | $13.8B | $24.5B | $14.8B | $14.5B |
| Loans, financing and debentures | $91.8B | $90.9B | $72.4B | $71.2B |
| Lease liabilities | $6.1B | $6.1B | $5.5B | $5.5B |
| Derivative financial instruments | $8.1B | $7.7B | $1.9B | $4.2B |
| Liabilities for assets acquisitions and subsidiaries | $77.1M | $99.3M | $93.8M | $205.6M |
| Provision for judicial liabilities | $2.8B | $2.9B | $2.9B | $3.3B |
| Employee benefit plans | $741.1M | $721.6M | $833.7M | $691.4M |
| Non-current provisions for employee benefits | $332.3M | $362.0M | $268.5M | $162.1M |
| Advances from customers | $74.7M | $74.7M | $74.7M | $136.2M |
| Other liabilities | $178.7M | $116.3M | $83.1M | $157.3M |
| Total non-current liabilities | $110.2B | $109.0B | $84.0B | $85.5B |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Sep 30, 2025 | Jun 30, 2025 |
|---|---|---|---|---|
| Cash and cash equivalents | $16.6B | $12.2B | $15.8B | $12.3B |
| Marketable securities | $9.6B | $10.2B | $7.7B | $8.1B |
| Trade accounts receivable | $6.2B | $5.8B | $6.1B | $7.3B |
| Inventories | $8.7B | $8.6B | $9.0B | $8.6B |
| Recoverable taxes | $860.4M | $946.8M | $962.2M | $997.7M |
| Current Tax Assets Income Tax Related | $858.6M | $726.7M | $526.0M | $450.2M |
| Derivative financial instruments | $3.1B | $2.9B | $1.4B | $1.1B |
| Advances to suppliers | $104.0M | $73.3M | $87.7M | $88.5M |
| Other assets | $783.5M | $819.2M | $977.2M | $994.6M |
| Total current assets | $46.9B | $42.2B | $42.6B | $39.9B |
| Marketable securities | $348.3M | $330.1M | $317.1M | $416.1M |
| Recoverable taxes | $924.4M | $944.7M | $965.2M | $962.3M |
| Deferred taxes | $122.7M | $112.2M | $1.5B | $2.4B |
| Derivative financial instruments | $8.8B | $9.0B | $6.8B | $4.1B |
| Advances to suppliers | $3.2B | $3.0B | $2.7B | $2.6B |
| Judicial deposits | $417.7M | $423.2M | $576.2M | $595.8M |
| Other assets | $193.8M | $194.2M | $191.8M | $196.8M |
| Biological assets | $27.6B | $26.5B | $24.4B | $23.2B |
| Investments accounted for using equity method | $1.1B | $1.1B | $1.4B | $1.4B |
| Property, plant and equipment | $63.7B | $64.0B | $64.5B | $65.0B |
| Right of use | $5.2B | $5.3B | $5.3B | $5.3B |
| Intangible | $12.5B | $12.7B | $13.2B | $13.4B |
| Total non-current assets | $124.2B | $123.6B | $121.8B | $119.5B |
| TOTAL ASSETS | $171.0B | $165.8B | $164.4B | $159.4B |
| Trade accounts payable | $5.6B | $5.0B | $5.4B | $6.0B |
| Loans, financing and debentures | $4.3B | $3.4B | $3.8B | $2.9B |
| Lease liabilities | $876.5M | $900.4M | $846.7M | $838.0M |
| Derivative financial instruments | $1.2B | $1.1B | $1.2B | $1.0B |
| Taxes payable | $173.1M | $252.1M | $184.3M | $210.7M |
| Income taxes payable | $70.2M | $29.4M | $239.2M | $280.6M |
| Payroll and charges | $864.3M | $720.4M | $1.1B | $857.0M |
| Dividends payable | $7.4M | $12.9M | $2.0M | $2.0M |
| Advances from customers | $120.3M | $124.1M | $168.8M | $146.6M |
| Other liabilities | $683.8M | $452.5M | $391.2M | $382.9M |
| Total current liabilities | $13.9B | $12.0B | $13.3B | $12.6B |
| Loans, financing and debentures | $88.4B | $87.3B | $89.2B | $88.7B |
| Lease liabilities | $5.8B | $5.9B | $6.0B | $5.9B |
| Derivative financial instruments | $7.3B | $7.5B | $6.4B | $4.6B |
| Provision for judicial liabilities | $2.8B | $2.8B | $2.8B | $2.8B |
| Employee benefit plans | $753.4M | $748.0M | $742.6M | $738.0M |
| Deferred taxes | $1.6B | $774.9M | — | — |
| Non-current provisions for employee benefits | $304.9M | $360.7M | $368.7M | $331.6M |
| Other liabilities | $381.8M | $329.5M | $144.5M | $149.7M |
| Total non-current liabilities | $107.3B | $105.6B | $105.8B | $103.5B |
| TOTAL LIABILITIES | $121.2B | $117.6B | $119.2B | $116.2B |
| Line item | Dec 31, 2025 · FY | Dec 31, 2024 · FY | Dec 31, 2023 · FY | Dec 31, 2022 · FY |
|---|---|---|---|---|
| Net income (loss) for the year | $13.4B | ($7.0B) | $14.1B | $23.4B |
| Depreciation, depletion and amortization | $10.9B | $8.9B | $7.0B | $7.2B |
| Depreciation, right-of-use assets | $384.0M | $349.1M | $321.3M | $232.0M |
| Interest expense on lease liabilities | $467.9M | $451.1M | $441.6M | $433.6M |
| Result from sale and disposal of property, plant and equipment, intangible and biological assets, net | $475.3M | $163.0M | $331.3M | $509.0K |
| Income (expense) from associates and joint ventures | $409.2M | $13.8M | $19.4M | ($284.4M) |
| Exchange rate and monetary variations, net | ($7.6B) | $15.9B | ($3.1B) | ($3.3B) |
| Interest expenses on financing, loans and debentures | $6.0B | $5.4B | $4.8B | $4.0B |
| Adjustments for finance costs | ($274.7M) | ($960.0M) | ($1.2B) | — |
| Accrual of interest on marketable securities | ($1.0B) | ($1.3B) | ($1.4B) | ($707.2M) |
| Amortization of transaction costs, premium and discounts | $101.9M | $80.1M | $67.4M | $69.9M |
| Derivative financial instruments, net | ($7.3B) | $9.1B | ($5.5B) | ($6.8B) |
| Gain on fair value adjustments (Note 29) | ($1.5B) | ($1.4B) | ($2.0B) | ($1.2B) |
| Deferred income tax and social contribution | $6.5B | ($7.4B) | $3.5B | $4.7B |
| Interest on actuarial liabilities and cost of current service | $79.3M | $75.8M | $69.2M | $59.3M |
| Provision for judicial liabilities, net | ($49.8M) | $138.3M | $139.9M | $88.2M |
| Provision (reversal) for doubtful accounts, net | $119.4M | $2.6M | $35.2M | $1.7M |
| Provision (reversal) for inventory losses, net | $141.6M | $77.4M | $31.4M | $56.1M |
| Provision (reversal) for loss of ICMS credits, net | $193.2M | $130.7M | $348.6M | $58.0M |
| Premium expenses on early settlements | $110.1M | — | — | — |
| Other | $92.6M | $69.5M | $51.8M | $2.8M |
| Trade accounts receivable | $1.6B | ($808.8M) | $2.2B | ($3.3B) |
| Inventories | ($216.4M) | ($863.6M) | ($48.7M) | ($968.0M) |
| Recoverable taxes | ($413.4M) | ($95.4M) | ($666.7M) | ($381.4M) |
| Other assets | $259.7M | $6.2M | $328.8M | $264.0M |
| Trade accounts payable | $6.6M | $2.2B | $463.0M | $1.5B |
| Taxes payable | $384.2M | $296.2M | $329.6M | $422.6M |
| Payroll and charges | ($91.5M) | $364.8M | $73.1M | $83.7M |
| Other liabilities | ($218.9M) | ($27.7M) | ($277.5M) | ($9.0M) |
| Cash generated from operations | $22.9B | $23.8B | $20.5B | $25.4B |
| Payment of interest on financing, loans and debentures | ($5.8B) | ($5.2B) | ($4.7B) | ($4.0B) |
| Adjustment for operating costs | $274.7M | — | — | — |
| Premium expenses on early settlements paid | ($110.1M) | — | — | — |
| Interest received on marketable securities | $1.2B | $1.5B | $681.3M | $544.8M |
| Payment of income taxes | ($289.5M) | ($366.3M) | ($308.0M) | ($306.5M) |
| Cash provided by operating activities | $18.2B | $20.6B | $17.3B | $21.6B |
| Additions to property, plant and equipment | ($4.6B) | ($9.2B) | ($11.7B) | ($9.8B) |
| Additions to intangible | ($82.5M) | ($162.0M) | ($104.9M) | ($90.5M) |
| Purchase of biological assets | ($7.9B) | ($7.2B) | ($5.8B) | ($5.0B) |
| Proceeds from sales of property, plant and equipment and biological assets | $122.7M | $168.0M | $183.6M | $251.2M |
| Capital increase in affiliates | ($22.0M) | ($41.3M) | ($48.5M) | ($67.0M) |
| Marketable securities, net | $2.9B | $206.0M | ($5.3B) | $67.4M |
| Advances for acquisition of wood from operations with development and partnerships | ($300.0M) | ($295.0M) | — | — |
| Dividends received | $8.8M | — | $44.8M | $6.6M |
| Acquisition of other investments | $9.4M | ($1.4B) | — | — |
| Line item | Jun 30, 2026 · YTD | Mar 31, 2026 · Q4 | Sep 30, 2025 · YTD | Jun 30, 2025 · YTD |
|---|---|---|---|---|
| Net income for the period | $6.1B | $4.3B | $13.3B | $11.4B |
| Depreciation, depletion and amortization | $5.8B | $2.7B | $7.9B | $5.2B |
| Depreciation, right-of-use assets | $167.9M | $81.3M | $277.9M | $167.7M |
| Interest expense on lease liabilities | $232.9M | $113.2M | $347.3M | $230.3M |
| Result from sale and disposal of property, plant and equipment, intangible and biological assets, net | ($188.3M) | ($32.1M) | $272.2M | $124.1M |
| Income (expense) from associates and joint ventures | $25.6M | $20.4M | $268.4M | $189.1M |
| Exchange rate and monetary variations, net | ($3.1B) | ($2.9B) | ($9.5B) | ($8.2B) |
| Interest expenses on financing, loans and debentures | $2.9B | $1.4B | $4.4B | $2.9B |
| Adjustments for finance costs | ($44.3M) | ($24.9M) | ($205.4M) | ($126.1M) |
| Amortization of transaction costs, premium and discounts | $84.6M | $58.5M | $75.9M | $48.2M |
| Derivative financial instruments, net | ($4.0B) | ($3.0B) | ($7.4B) | ($6.4B) |
| Premium expenses on early settlements | $129.8M | $129.0M | $89.0M | — |
| Accrual of interest on marketable securities | ($648.1M) | ($311.6M) | ($769.9M) | ($516.6M) |
| Fair value adjustment of biological assets | ($1.2B) | — | $73.2M | $73.2M |
| Deferred income tax and social contribution | $3.0B | $2.2B | $6.5B | $5.6B |
| Interest on actuarial liabilities and cost of current service | $40.4M | $20.2M | $59.5M | $39.6M |
| Provision for judicial liabilities, net | $28.3M | $30.8M | ($41.6M) | ($36.6M) |
| Provision (reversal) for doubtful accounts, net | ($28.5M) | ($16.6M) | $103.5M | $45.5M |
| Provision (reversal) for inventory losses, net | $16.2M | $2.1M | $24.0M | $13.8M |
| Provision (reversal) for loss of ICMS credits, net | ($3.9M) | ($13.2M) | $151.7M | $83.9M |
| Other | $44.1M | $17.7M | $65.6M | $33.9M |
| Trade accounts receivable | $215.6M | $638.3M | $1.9B | $896.1M |
| Inventories | ($362.3M) | ($124.7M) | ($730.9M) | ($402.4M) |
| Recoverable taxes | ($154.3M) | ($116.7M) | ($334.3M) | ($216.7M) |
| Other assets | $126.0M | $23.6M | ($128.6M) | ($94.1M) |
| Trade accounts payable | $801.3M | $68.8M | $101.4M | $405.2M |
| Taxes payable | ($93.0M) | ($113.3M) | $287.2M | $313.9M |
| Payroll and charges | ($265.3M) | ($411.1M) | ($164.5M) | ($370.3M) |
| Other liabilities | $96.6M | ($64.4M) | ($201.6M) | ($210.2M) |
| Cash generated from operations | $9.7B | $4.7B | $16.7B | $11.1B |
| Payment of interest on financing, loans and debentures | ($2.6B) | ($1.7B) | ($4.8B) | ($2.9B) |
| Adjustment for operating costs | $44.3M | $24.9M | — | — |
| Premium expenses on early settlements paid | ($129.8M) | ($129.0M) | ($89.0M) | — |
| Interest received on marketable securities | $363.2M | $114.2M | $969.1M | $582.8M |
| Payment of income taxes | ($127.4M) | ($68.7M) | ($230.0M) | ($182.7M) |
| Cash provided by operating activities | $7.3B | $2.9B | $12.8B | $8.8B |
| Additions to property, plant and equipment | ($1.8B) | ($890.6M) | ($3.4B) | ($2.6B) |
| Additions to intangible | ($71.4M) | ($4.1M) | ($59.6M) | ($22.1M) |
| Purchase of biological assets | ($3.6B) | ($2.1B) | ($6.3B) | ($3.6B) |
| Proceeds from sales of property, plant and equipment and biological assets | $250.7M | $103.5M | $114.2M | $78.5M |
| Capital increase in affiliates | ($2.5M) | — | ($22.0M) | ($7.3M) |
| Marketable securities, net | $531.6M | ($62.1M) | $5.1B | $4.8B |
| Advances for acquisition of wood from operations with development and partnerships | ($433.3M) | ($257.2M) | ($224.7M) | ($124.6M) |
| Dividends received | $3.9M | — | $8.8M | $8.8M |
| Cash used in investing activities | ($5.2B) | ($3.2B) | ($4.8B) | ($1.5B) |
Suzano SA ADR score and earnings-call analysis · All covered companies
Figures as reported in SEC filings. General information, not investment advice.